Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective raised by Nomura to $165.00 in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Nomura’s price objective would suggest a potential upside of 48.14% from the stock’s current price.
Other equities research analysts have also issued reports about the company. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Citigroup decreased their price target on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research report on Friday, February 9th. Leerink Swann decreased their price objective on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. BMO Capital Markets increased their price objective on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 9th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $151.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and twenty have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $155.95.
NASDAQ ALXN opened at $111.38 on Thursday. The company has a market cap of $24,746.26, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 1.00 and a beta of 1.13. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 EPS. analysts forecast that Alexion Pharmaceuticals will post 6.12 earnings per share for the current fiscal year.
In other news, SVP Heidi L. Wagner sold 698 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.35, for a total value of $83,306.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Heidi L. Wagner sold 655 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the transaction, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock worth $3,345,708 over the last 90 days. 4.35% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Delpha Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals in the 4th quarter worth $102,000. Valeo Financial Advisors LLC bought a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth $147,000. CNB Bank bought a new position in shares of Alexion Pharmaceuticals in the 4th quarter worth $150,000. Beacon Investment Advisory Services Inc. bought a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth $201,000. Finally, Lourd Capital LLC bought a new position in shares of Alexion Pharmaceuticals in the 4th quarter worth $221,000. Institutional investors and hedge funds own 95.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals (ALXN) Given New $165.00 Price Target at Nomura” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/14/alexion-pharmaceuticals-alxn-given-new-165-00-price-target-at-nomura.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.